Zhongyuan Union Stem Cell Bio-Engineering Buys Zhicheng For RMB 800 Million
This article was originally published in PharmAsia News
Executive Summary
Zhongyuan Union Stem Cell Bio-Engineering said May 22 it would buy 100% of the equity of Shanghai Zhicheng Biotechnology for RMB 800 million ($129 million) using 70% paid by shares at RMB 24.5 a share and 30% by cash.